Meet the New Biomarkers: Personalizing Cancer Care in 2020

Register now for this live, CE-certified Webinar! An expert nursing panel will discuss best practices for the clinical use of biomarker testing in cancer care, with a focus on new and evolving biomarkers in lung cancer and gastrointestinal malignancies.

During the live program, you will have opportunities to interact with the presenting faculty through interactive patient case scenarios and an audience question and answer session.


Overview of Current Status of Biomarker Testing in Cancer Care Elisabeth King, AGN, AOCNP, FNP, RN

  • Review of precision medicine and biomarker driven care
  • Overview of testing modalities
  • Case discussion

New and Evolving Biomarkers in Lung Cancer – Diane G. Cope, PhD, ARNP-BC, AOCNP

  • PD-L1
  • ROS1
  • NTRK
  • RET
  • METex14
  • Case discussion

New and Evolving Biomarkers in Gastrointestinal Malignancies – Sara Toth, RN, MSN, FNP-C, AOCNP, AGN-BC

  • BRAF
  • HER2
  • BRCA1/2
  • Case discussion

Final Panel Discussion and Audience Q&A: Clinical Pearls and Future Directions in Molecular Profiling/Precision Medicine


Date / Time
Event Details


Program Director
Elisabeth King, RN, FNP, AGN, AOCNP

Executive Director of Genomics and Precision Medicine
City of Hope
Duarte, California

Diane G. Cope, PhD, ARNP-BC, AOCNP

Oncology Nurse Practitioner
Chair, Clinical Directions Team
Florida Cancer Specialists and Research Institute
Fort Myers, Florida


Nurse Practitioner
APP Services
Texas Oncology
Ft Worth, Texas

Goal Statement
The goal of this activity is to improve the knowledge and competence of oncology nurses to understand and explain the use of key biomarkers to patients with cancer.

Target Audience 
This program is intended for nurses and other healthcare providers who care for patients with cancer.

Learning Objectives 

  • Discuss the importance of predictive biomarkers and how they guide therapeutic decisions for patients with cancer
  • Evaluate the available data, indications, and expert recommendations to determine which biomarkers should be tested in your patients with cancer
  • Explain to patients the need for an additional biopsy to test for appropriate biomarkers in cases where the initial biopsy sample was insufficient or if the biomarker status was previously unknown
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor


Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

A maximum of 1.5 contact hours may be earned for successful completion of this activity.

Disclosure of Conflicts of Interest 
Annenberg Center for Health Sciences requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.